Ownership and insider activity for Acurx Pharmaceuticals, Inc. (ACXP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections.
Price
| Price | $1.38 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-04-20 | Sailer Carl | A-Award | 2,150 | $5K |
| 2026-04-20 | DEAN JACK H | A-Award | 2,150 | $5K |
| 2026-04-20 | Donohue James J. | A-Award | 2,150 | $5K |
| 2026-04-20 | HARRISON THOMAS L | A-Award | 2,150 | $5K |
| 2026-04-20 | Scodari Joseph C | A-Award | 2,150 | $5K |
| 2026-04-20 | DELUCCIA ROBERT J | A-Award | 37,100 | $88K |
| 2026-04-20 | LUCI DAVID P | A-Award | 37,100 | $88K |
| 2026-04-20 | Shawah Robert G. | A-Award | 25,900 | $61K |
| 2025-02-05 | Shawah Robert G. | A-Award | 145,500 | $116K |
| 2025-02-05 | LUCI DAVID P | A-Award | 250,000 | $200K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | $3.2M | $13.0M | $9.1M | $7.5M | $3.7M | $7.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | $129159 | $51127 | $48417 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | $16625 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.7M | $472556 | $843909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Long-term Debt | 0 | $49878 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.7M | $522434 | $843909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Retained Earnings | -$9.2M | -$13.8M | -$26.5M | -$38.6M | -$53.2M | -$67.3M | -$75.3M |
| Total Equity | $819854 | $2.7M | $12.4M | $7.3M | $4.7M | $615121 | $5.3M |
| Total Debt | 0 | $66503 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$2.5M | -$3.1M | -$13.0M | -$9.1M | -$7.5M | -$3.7M | -$7.6M |
| Working Capital | $819854 | $2.8M | $12.4M | $7.3M | $4.7M | $615121 | $5.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.88 |
Profitability
| Return on Equity | -124.74% |
| Return on Invested Capital | -94.08% |
| Return on Assets | -68.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADIL · APRE · APVO · BCDA · BCLI · CELZ · GLTO
Explore sector: Healthcare · Biotechnology
More sections of ACXP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks